The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

被引:196
作者
Zhou, Ledu [1 ]
Huang, Yun [1 ]
Li, Jingdong [1 ]
Wang, Zhiming [1 ]
机构
[1] Cent S Univ, XiangYa Hosptial, Dept Gen Surg, Changsha 410078, Hunan, Peoples R China
关键词
Hepatocellular carcinoma; mTOR; S6; Akt; PTEN; p27; Prognosis; CANCER; TARGET; PATHOGENESIS; INHIBITION; P27(KIP1); RAPAMYCIN; SURVIVAL; UPSTREAM; RISK;
D O I
10.1007/s12032-009-9201-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective The mammalian target of rapamycin (mTOR) pathway, an important regulator of multiple cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. It has achieved considerable importance. This study was conducted to determine the status of the mTOR pathway in human hepatocellular carcinoma (HCC) and to investigate its relationship with the prognosis of HCC. Methods PTEN, pAkt, p27, and pS6 expression in cryo-sections gathered from 528 cases with HCC by the method of immunohistochemistry. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of HCC. Results The mTOR pathway was more significantly altered in high-grade tumors, and tumors with poor prognostic features. Especially, pAkt and cytoplasmic p27 expression showed the strongest associations with pathological parameters of HCC. Statistical analysis showed that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different overall survival rates relative to those not expressing these proteins. Cox multi-factor analysis showed that tumor differentiation (P = 0.006), vascular invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC. Conclusion: Expression of the mTOR pathway components, which are related with the transferability and invasive capacity of HCC cells, may be used as prognostic indicators in HCC.
引用
收藏
页码:255 / 261
页数:7
相关论文
共 30 条
[1]   Molecular Mechanisms of Hepatocellular Carcinoma [J].
Aravalli, Rajagopal N. ;
Steer, Clifford J. ;
Cressman, Erik N. K. .
HEPATOLOGY, 2008, 48 (06) :2047-2063
[2]   Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].
Baylin, SB ;
Ohm, JE .
NATURE REVIEWS CANCER, 2006, 6 (02) :107-116
[3]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[4]  
Blum HE, 2005, WORLD J GASTROENTERO, V11, P7391
[5]   Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer [J].
Chan, S .
BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1420-1424
[6]   Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women [J].
Donato, F ;
Tagger, A ;
Gelatti, U ;
Parrinello, G ;
Boffetta, P ;
Albertini, A ;
Decarli, A ;
Trevisi, P ;
Ribero, ML ;
Martelli, C ;
Porru, S ;
Nardi, G .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (04) :323-331
[7]   Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis [J].
El-Serag, Hashem B. ;
Rudolph, Lenhard .
GASTROENTEROLOGY, 2007, 132 (07) :2557-2576
[8]   Hepatocellular carcinoma pathogenesis: from genes to environment [J].
Farazi, Paraskevi A. ;
DePinho, Ronald A. .
NATURE REVIEWS CANCER, 2006, 6 (09) :674-687
[9]   Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection [J].
Gao, Qiang ;
Qiu, Shuang-Jian ;
Fan, Jia ;
Zhou, Jian ;
Wang, Xiao-Ying ;
Xiao, Yong-Sheng ;
Xu, Yang ;
Li, Yi-Wei ;
Tang, Zhao-You .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2586-2593
[10]   An expanding role for mTOR in cancer [J].
Guertin, DA ;
Sabatini, DM .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (08) :353-361